For instance, the AMLFusionChip [14] only included three major types of rearrangements in AML: AML1-ETO, CBFB-MYH11, and 11q23/MLL abnormalities (MLL-AF9, MLL-ENL, MLL-AF6, and MLL-AF10); the gel-based biochip developed by Nasedkina et al. [12] addressed 13 fusion variants in 7 leukemia translocations. This evidence concerns the gene CBFB and leukemia.